Photodiagnosis and Photodynamic Therapy
Volume 8, Issue 4 , Pages 291-296 , December 2011

Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma

  • Renata Sanovic

      Affiliations

    • Institute of Physiology and Pathophysiology, Paracelsus Medical University Salzburg, Strubergasse 21, 5020 Salzburg, Austria
    • ,
  • Thomas Verwanger

      Affiliations

    • Department of Molecular Biology, University of Salzburg, Hellbrunnerstr. 34, 5020 Salzburg, Austria
    • ,
  • Arnulf Hartl

      Affiliations

    • Institute of Physiology and Pathophysiology, Paracelsus Medical University Salzburg, Strubergasse 21, 5020 Salzburg, Austria
    • ,
  • Barbara Krammer

      Affiliations

    • Department of Molecular Biology, University of Salzburg, Hellbrunnerstr. 34, 5020 Salzburg, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 662 8044 5703; fax: +43 662 8044 150.

References 

  1. Gomer CJ. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol. 1991;54:1093–1107
  2. Keller SM. Photodynamic therapy. Biology and clinical application. Chest Surg Clin N Am. 1995;5:121–137
  3. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg. 2002;20:3–7
  4. Patrice T, Olivier D, Bourre L. PDT in clinics: indications, results, and markets. J Environ Pathol Toxicol Oncol. 2006;25:467–485
  5. Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Bba-Rev Cancer. 2007;1776:86–107
  6. Henderson BW, Dougherty TJ. How does photodynamic therapy work?. Photochem Photobiol. 1992;55:145–157
  7. Butterweck V, Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr. 2007;157:356–361
  8. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000;294:88–95
  9. Galeotti N, Vivoli E, Bilia AR, Vincieri FF, Ghelardini C. St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase C gamma and epsilon activity. Biochem Pharmacol. 2010;79:1327–1336
  10. Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci. 2010;11:562–594
  11. Engelhardt V, Krammer B, Plaetzer K. Antibacterial photodynamic therapy using water-soluble formulations of hypericin or mTHPC is effective in inactivation of Staphylococcus aureus. Photochem Photobiol Sci. 2010;9:365–369
  12. Saw CL, Heng PW, Olivo M. Potentiation of the photodynamic action of hypericin. J Environ Pathol Toxicol Oncol. 2008;27:23–33
  13. Blank M, Lavie G, Mandel M, Keisari Y. Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncol Res. 2000;12:409–418
  14. Chen B, Xu Y, Roskams T, et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer. 2001;93:275–282
  15. Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res. 2010;46:216–226
  16. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6:535–545
  17. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002;62:1604–1608
  18. Korbelik M, Sun JH. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother. 2006;55:900–909
  19. Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr. 2006;16:279–305
  20. Chen B, Roskams T, de Witte PA. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol. 2002;76:509–513
  21. Olivo M, Chin W. Perylenequinones in photodynamic therapy: cellular versus vascular response. J Environ Pathol Toxicol Oncol. 2006;25:223–237
  22. Blank M, Kostenich G, Lavie G, Kimel S, Keisari Y, Orenstein A. Wavelength-dependent properties of photodynamic therapy using hypericin in vitro and in an animal model. Photochem Photobiol. 2002;76:335–340
  23. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res. 2001;21:4271–4277
  24. Chen B, Roskams T, Xu Y, Agostinis P, de Witte PA. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int J Cancer. 2002;98:284–290
  25. Sosa S, Pace R, Bornancin A, et al. Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L.. J Pharm Pharmacol. 2007;59:703–709
  26. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg. 1996;14:329–334
  27. Chen WR, Huang Z, Korbelik M, Nordquist RE, Liu H. Photoimmunotherapy for cancer treatment. J Environ Pathol Toxicol Oncol. 2006;25:281–291
  28. Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci. 2011;

PII: S1572-1000(11)00390-5

doi: 10.1016/j.pdpdt.2011.04.003

Photodiagnosis and Photodynamic Therapy
Volume 8, Issue 4 , Pages 291-296 , December 2011

Article Tools

* Image Usage & Resolution